Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trans Sodium Crocetinate with Radiation and Temozolomide in Newly Diagnosed Glioblastoma
NCT03393000Phase 3Terminated
- Sponsor
- Diffusion Pharmaceuticals Inc.
- Start
- Jan 2018
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of trans sodium crocetinate in glioblastoma (GBM), sponsored by Diffusion Pharmaceuticals Inc.. Started Jan 2018; status: terminated.
02
Drugs
trans sodium crocetinate
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT03393000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03393000.